Tv-4710    (DrugBank: -)

1 disease
IDDisease name (Link within this page)Number of trials
49Systemic lupus erythematosus5

49. Systemic lupus erythematosus    [ 827 clinical trials,   638 drugs,   (DrugBank: 168 drugs),   108 drug target genes,   191 drug target pathways]
Searched query = "Systemic lupus erythematosus", "SLE"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
5 / 827 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2005-001391-12-GB
(EUCTR)
12/10/200515/06/2005A multi-national, multi-centre, randomized, double-blind, placebo-controlled, multiple-dose, parallel-group study to assess the efficacy, tolerability and safety of three doses of edratide (TV-4710) for injection administered subcutaneously to systemic lupus erythematosus (SLE) patients - PRELUDEA multi-national, multi-centre, randomized, double-blind, placebo-controlled, multiple-dose, parallel-group study to assess the efficacy, tolerability and safety of three doses of edratide (TV-4710) for injection administered subcutaneously to systemic lupus erythematosus (SLE) patients - PRELUDE Systemic lupus erythematosus (SLE)
MedDRA version: 7.1;Level: PT;Classification code 10042945
TEVA Pharmaceutical Industries, Ltd.NULLNot Recruiting Female: yes
Male: yes
260Phase 2Hungary;Spain;Germany;Italy;United Kingdom
2EUCTR2005-001391-12-DE
(EUCTR)
23/09/200515/07/2005A multi-national, multi-centre, randomized, double-blind, placebo-controlled, multiple-dose, parallel-group study to assess the efficacy, tolerability and safety of three doses of edratide (TV-4710) for injection administered subcutaneously to systemic lupus erythematosus (SLE) patients - PRELUDEA multi-national, multi-centre, randomized, double-blind, placebo-controlled, multiple-dose, parallel-group study to assess the efficacy, tolerability and safety of three doses of edratide (TV-4710) for injection administered subcutaneously to systemic lupus erythematosus (SLE) patients - PRELUDE Systemic lupus erythematosus (SLE)
MedDRA version: 7.1;Level: PT;Classification code 10042945
Product Name: edratide
Product Code: TV-4710
INN or Proposed INN: edratide
TEVA Pharmaceutical Industries, Ltd.NULLNot RecruitingFemale: yes
Male: yes
260Hungary;United Kingdom;Germany;Spain;Italy
3EUCTR2005-001391-12-ES
(EUCTR)
01/09/200507/07/2005A multi-national, multi-centre, randomized, double-blind, placebo-controlled, multiple-dose, parallel-group study to assess the efficacy, tolerability and safety of three doses of edratide (TV-4710) for injection administered subcutaneously to systemic lupus erythematosus (SLE) patients - PRELUDEA multi-national, multi-centre, randomized, double-blind, placebo-controlled, multiple-dose, parallel-group study to assess the efficacy, tolerability and safety of three doses of edratide (TV-4710) for injection administered subcutaneously to systemic lupus erythematosus (SLE) patients - PRELUDE Systemic lupus erythematosus (SLE)
MedDRA version: 7.1;Level: PT;Classification code 10042945
Product Name: edratide
Product Code: TV-4710
INN or Proposed INN: edratide
Product Name: edratide
Product Code: TV-4710
INN or Proposed INN: edratide
Product Name: edratide
Product Code: TV-4710
INN or Proposed INN: edratide
TEVA Pharmaceutical Industries, Ltd.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
260Hungary;Germany;United Kingdom;Spain;Italy
4EUCTR2005-001391-12-IT
(EUCTR)
28/07/200523/03/2006A Multi-National, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Parallel Group Study to Assess the Efficacy, Tolerability and Safety of Three Doses of Edratide TV-4710 for Injection Administered Subcutaneously to Systemic Lupus Erythematosus SLE patientsA Multi-National, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Parallel Group Study to Assess the Efficacy, Tolerability and Safety of Three Doses of Edratide TV-4710 for Injection Administered Subcutaneously to Systemic Lupus Erythematosus SLE patients Treatment of active SLE patients who are concurrently undergoing a regimented program of decreased steroid use.
MedDRA version: 6.1;Level: PT;Classification code 10042945
Product Name: Edratide Acetate
Product Code: TV-4710
Product Name: Edratide Acetate
Product Code: TV-4710
Product Name: Edratide Acetate
Product Code: TV-4710
TEVANULLNot RecruitingFemale: yes
Male: yes
260Hungary;Germany;United Kingdom;Spain;Italy
5EUCTR2005-001391-12-HU
(EUCTR)
27/07/200515/06/2005A multi-national, multi-centre, randomized, double-blind, placebo-controlled, multiple-dose, parallel-group study to assess the efficacy, tolerability and safety of three doses of edratide (TV-4710) for injection administered subcutaneously to systemic lupus erythematosus (SLE) patients - PRELUDEA multi-national, multi-centre, randomized, double-blind, placebo-controlled, multiple-dose, parallel-group study to assess the efficacy, tolerability and safety of three doses of edratide (TV-4710) for injection administered subcutaneously to systemic lupus erythematosus (SLE) patients - PRELUDE Systemic lupus erythematosus (SLE)
MedDRA version: 7.1;Level: PT;Classification code 10042945
Product Name: edratide
Product Code: TV-4710
INN or Proposed INN: edratide
TEVA Pharmaceutical Industries, Ltd.NULLNot RecruitingFemale: yes
Male: yes
260Hungary;Germany;United Kingdom;Spain;Italy